| 英文摘要 |
Carbamazepine is the second major drug to induce severe cutaneous reactions in Taiwan, but only 38% of the prescriptions are used as indications . Many neurologists and psychiatrists are liable to law suit for the drug hazard in Taiwan. In this issue of Taiwanese Journal of Psychiatry, Lin has reviewed the risk factors and management of mood stabilizers associated Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) . After the acceptance for publication of that review, a landmark article proving the effect of HLA-B*1502 screening to avoid carbamazepineinduced toxic effects in Taiwan was published in New England Journal of Medicine . Drug Hazard Relief Act was also revised on April 19, 2011 in the Legislative Yuan to remove restraints on drug hazard relief of “off labeled use” of medications (http://www.fda.gov.tw/news.aspx?newssn). This companion invited editorial is just in time to comment on these two breakthrough events. |
本站僅提供期刊文獻檢索。
